Category «Uncategorized»

Amisulpride, アミスルプリド ,

Amisulpride FDA 2020, Barhemsys APPROVED, 2020/2/27 Name Amisulpride (INN); Deniban (TN); Solian (TN) アミスルプリド; Formula C17H27N3O4S CAS 71675-85-9 Mol weight 369.479 Antipsychotic, Dopamine receptor antagonist, Neuropsychiatric agent amisulpride(标准品) 275-831-7 [EINECS] Synthesis ReferenceUS4401822 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide Amisulpride CAS Registry Number: 71675-85-9 CAS Name: 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide Additional Names: 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-o-anisamide; aminosultopride Manufacturers’ Codes: DAN-2163 Trademarks: Deniban (Synthelabo); Socian (Synthelabo); Solian (Synthelabo); Sulamid (Baldacci) Molecular Formula: C17H27N3O4S Molecular Weight: 369.48 Percent Composition: C 55.26%, …

リメゲパント硫酸塩; Rimegepant sulfate

Rimegepant Molecular FormulaC28H28F2N6O3 Monoisotopic mass534.219116 Da 1289023-67-1 [RN] 1-Piperidinecarboxylic acid, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl ester 9751 BMS 927711 Antimigraine, Calcitonin receptor-like receptor antagonist Treatment of migraine Rimegepant sulfate (USAN) リメゲパント硫酸塩; Formula (C28H28F2N6O3)2. H2SO4. 3H2O CAS 1374024-48-2 Mol weight 1221.2386 Nurtec ODT, FDA 2020, 2020/2/27 fda approved Biohaven Pharmaceuticals developed Rimegepant, also known as BMS-927711 (acquired in 2016 from …

Tranilast

Tranilast Molecular FormulaC18H17NO5 Average mass327.331 Da 2-{[(2E)-3-(3,4-Dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid 3,4-DAA 5070 53902-12-8 [RN] Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s. Kissei has developed and launched tranilast in Japan and South Korea for …

Enavogliflozin, DWP-16001

Enavogliflozin, DWP-16001 (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol CAS: 1415472-28-4Chemical Formula: C24H27ClO6Molecular Weight: 446.92Elemental Analysis: C, 64.50; H, 6.09; Cl, 7.93; O, 21.48 Green Cross Corp INNOVATOR Daewoong Pharmaceutical Co Ltd Enavogliflozin is an antidiabetic (hypoglycemic). Daewoong is investigating DWJ-304 , a sodium/glucose cotransporter 2 (SGLT-2) inhibitor, for treating type 2 diabetes. By February 2017, preclinical development was underway. …

LYS 228

LYS228 BOS-228 LYS-228 Molecular Formula, C16-H18-N6-O10-S2 Molecular Weight, 518.4783 (3S,4R)-3-((Z)-2-(2-Ammoniothiazol-4-yl)-2-((1-carboxycyclopropoxy)imino)acetamido)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidine-1-sulfonate RN: 1810051-96-7 UNII: 29H7N9XI1B UNII-005B24W9YP 005B24W9YP Lys-228 trihydrate 2091840-43-4 Yclopropanecarboxylic acid, 1-(((Z)-(1-(2-amino-4-thiazolyl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-3-oxazolidinyl)methyl)-1-sulfo-3-azetidinyl)amino)ethylidene)amino)oxy)-, hydrate (1:3) 1-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-[[(3S,4R)-2-oxo-4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-1-sulfoazetidin-3-yl]amino]ethylidene]amino]oxycyclopropane-1-carboxylic acid;trihydrate BOS-228 (LYS-228) is a monobactam discovered at Novartis and currently in phase II clinical development at Boston Pharmaceuticals for the treatment of complicated urinary tract infection and complicated intraabdominal …

ADX-103

ADX-103 CAS 916056-81-0 Preclinical, Antiinflammatory Ophthalmic Agents, Diabetic Retinopathy, Agents for Ophthalmic Drugs MF C16 H16 N2 O2 5-Amino-α,α-dimethyl-2-phenyl-6-benzoxazolemethanol MW 268.31 6-Benzoxazolemethanol, 5-amino-α,α-dimethyl-2-phenyl- Aldeyra Therapeutics Inc ADX-103 , an aldehyde trap being investigated by Aldeyra for the treatment of dry eye syndrome; in May 2018, preclinical data were presented at 2018 ARVO Meeting in Honolulu, HI. Aldeyra, in collaboration with …

Islatravir (MK-8591, EFdA)

Islatravir (MK-8591, EFdA) 2′-Deoxy-4′-ethynyl-2-fluoroadenosine Molecular FormulaC12H12FN5O3 Average mass293.254 Da 865363-93-5 2′-Deoxy-4′-ethynyl-2-fluoroadenosine 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Adenosine, 2′-deoxy-4′-C-ethynyl-2-fluoro- (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol 2′-deoxy-4′-c-ethynyl-2-fluoroadenosine 865363-93-5 [RN] 9H-Purin-6-amine, 9-(2-deoxy-4-C-ethynyl-β-D-erythro-pentofuranosyl)-2-fluoro- E2FDA (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol MK-8591 UNII:QPQ082R25D FDA APPROVED 2026, 4/20/2026, doravirine and islatravir, Idvynso To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable …

LNS-8801 (SRR G-1)

LNS-8801 (SRR G-1) CAS 925419-53-0 Chemokine receptor-like 2 agonist C21 H18 Br N O3, 412.28 Ethanone, 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- 1-((3aS,4R,9bR)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)ethan-1-one 1-[(3aS,4R,9bR)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone G 1 G 1 (estrogen receptor agonist) Linnaeus Therapeutics Inc NOTE 1-((3aR,4S,9bR)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)ethan-1-one (RSS G-1 or LNS8812) Novel crystalline forms of an enantiomerically purified LNS-8801 (SRR G-1), or a derivative useful for treating cancer, hearing disorder, depression and myocardial …

CC-90010

CC-90010 C21 H21 N O4 S, 383.46 CAS 1706738-98-8 1(2H)-Isoquinolinone, 4-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl- 4-[2-(Cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl-1(2H)-isoquinolinone 4-[2-(Cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one 4-[2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Quanticel Pharmaceuticals Inc, Michael John BennettJuan Manuel BetancortAmogh BoloorStephen W. KaldorJeffrey Alan StaffordJames Marvin Veal Celgene (now a wholly owned subsidiary of Bristol-Myers Squibb ) , following its acquisition of Quanticel , is developing CC-90010, an oral inhibitor of BET (bromodomain and extraterminal) proteins, for the potential treatment …

Delgocitinib

Delgocitinib デルゴシチニブ 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)- 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile Formula C16H18N6O CAS 1263774-59-9 Mol weight 310.3537 Approved, Japan 2020, Corectim, 2020/1/23, atopic dermatitis, Japan Tobacco (JT) Torii 7/23/2025 fda approved, Anzupgo To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response UNII-9L0Q8KK220, JTE-052, LP-0133, ROH-201, 9L0Q8KK220, LEO 124249A, LEO 124249, HY-109053 CS-0031558, D11046, GTPL9619, JTE-052A, JTE052 Delgocitinib, also known as LEO-124249 and JTE052, is a …